CSIMarket
 
Theralink Technologies Inc   (OBMP)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 6,152
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -60
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Theralink Technologies Inc
Theralink Technologies, Inc., previously known as OncBioMune Pharmaceuticals, Inc., was a clinical-stage biopharmaceutical company that focused on developing novel cancer immunotherapy products and had a proprietary vaccine technology. On June 5, 2020, Theralink Technologies, Inc. acquired the assets of Avant Diagnostics, Inc., a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of patented proprietary data-generating assays, through the Asset Sale Transaction. The company purchased substantially all of the assets of Avant, and assumed some of its liabilities. In consideration for the Asset Sale Transaction, Theralink Technologies, Inc. issued to Avant 1,000 shares of a newly created Series D-1 Preferred Stock, which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the effectiveness of an increase of the Companyes authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,549,184 shares of the Companyes common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction, and controlled the Companyes Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Therefore, the Asset Sale Transaction was accounted for as an asset acquisition of the Companyes net assets by Avant and a recapitalization of Avant. On June 5, 2020, Theralink Technologies, Inc. entered into an employment agreement with Dr. Michael Ruxin to serve as the companyes Chief Executive Officer, President and a director, entered into an employment agreement with Jeffery Busch to serve as the companyes Chairman of the Board of Directors, and appointed Yvonne Fors to its Board of Directors, pursuant to the Asset Purchase Agreement. On August 14, 2020, the Board appointed Mr. Andrew Kucharchuk as Acting Chief Financial Officer of the Company, and approved a change in the Companyes fiscal year-end from December 31 to September 30, effective immediately for the current fiscal year, and for all subsequent years until such time as the Board resolves to amend such fiscal year-end. The fiscal year has been changed to conform to the September 30 fiscal year-end of Avant, which is the historical registrant as a result of the Asset Sale Transaction consummated on June 5, 2020, and therefore, no transition report is required. On September 24, 2020, Andrew Kucharchuk resigned from his position as Acting Chief Financial Officer. Mr. Kucharchuk continues to serve as a director on the Companyes Board of Directors. On the same day, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. On April 1, 2022, the Board of Directors was expanded to six members, and Danica Holley and Matthew Schwartz were appointed to these newly created positions. Theralink Technologies, Inc. is a commercial-stage, precision medicine, molecular data-generating company that focuses on the development and commercialization of a series of proprietary data-generating assays that may provide important actionable information for physicians, patients and biopharmaceutical companies, in the area of oncology. The Company aims to commercialize the technology originally developed by Theranostics Health, Inc. The technology is differentiated due to the exclusive license agreement with George Mason University (eGMUe), the patent portfolio licensed from GMU and the National Institute of Health (eNIHe), access to GMUes well-p. In addition to its current product offerings, Theralink is also actively pursuing the development of new products, with a focus on expanding its precision oncology offerings. The company is working to develop assays that can be used to identify specific molecular targets that are associated with various types of cancer, with the goal of enabling more targeted and effective treatments for patients. Theralink has also established partnerships with other companies in the biopharmaceutical industry, in order to leverage its proprietary technology to support drug development and clinical trials. Through these partnerships, Theralink aims to generate additional revenue streams and expand the reach of its technology into new areas of oncology research and treatment. Overall, Theralink Technologies is a cutting-edge biopharmaceutical company with a focus on precision medicine and molecular data-generating assays for the diagnosis and treatment of cancer. With a strong patent portfolio and a team of experienced industry professionals, the company is well-positioned for continued growth and success in the years to come.


   Company Address: 15000 W. 6th Avenue Golden 80401 CO
   Company Phone Number: 420-0074   Stock Exchange / Ticker: OBMP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Theralink Technologies Inc

Theralink Technologies Inc Outshines Competitors with Marvelous Top-line Surge in Third Quarter of 2023

Theralink Technologies Inc is a major player in the pharmaceutical industry, specializing in the development and production of various medical preparations. Despite a significant surge in revenue, the company's profitability failed to show any improvement in the financial reporting period from April to June 30, 2023. The company reported zero gain at $0.00 per share during this period.
Although the company faced challenges in maintaining profitability, Theralink Technologies Inc experienced a notable increase in revenue, which jumped by 23.283% to $0.20 million compared to the same period the previous year. This growth in revenue outpaced its industry peers in the Major Pharmaceutical Preparations sector, as other companies in the industry only showed a revenue elevation of 3.05% during the same period.

Theralink Technologies Inc

Theralink Technologies Inc. Reports Remarkable 770% Revenue Growth, but Net Deficit Raises Concerns of Financial Instability

Theralink Technologies Inc., a biotechnology company that specializes in precision medicine, recently reported its financial results for the time-frame closing March 31 2023. While the company's revenue showed a remarkable growth of 770.703%, to $0.17 million from $0.02 million in the comparable reporting period a year ago, this is not indicative of its overall financial health. In fact, a closer look at the company's performance reveals that it is far from being financially stable.
For the financial time-frame ending on March 31 2023, Theralink Technologies Inc. realized a net deficit of $-8.566 million, which is larger than the $-1.856 million recorded in the previous year. This is a concerning sign for investors that have invested in Theralink Technologies Inc., as it appears that the company is heading towards insolvency. This net deficit, coupled with the company's inability to achieve profitability, makes investing in Theralink Technologies Inc a risky proposition.






 

Theralink Technologies Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com